Atlas Trials

Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

RecordFirmDate
Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer (NCT07530445)Sun Yat-sen University2026-03-23

Track Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer automatically

Every clearance here is in the API, with alerts when new ones post.